Atopic Dermatitis Research Review

 28 October 2021 – Dermatitis Research Review Issue 7

In this edition we feature:

–  Heads Up confirms superior efficacy of oral upadacitinib versus dupilumab
–  Identification of four paediatric AD subtypes
–  Superior PROMs in Japanese versus Dutch patients on dupilumab therapy
–  Delgocitinib ointment efficacious in Japanese paediatric patients
–  TRuE AD clinical program finds topical ruxolitinib efficacious in adolescent and adult patients
–  Practical management of patients with AD on dupilumab
–  Small but significant rates of treatment difficulties in paediatric patients on dupilumab
–  Low persistence of isothiazolinones in clothes after machine washing
–  Incidence rates of occupational contact dermatitis in Denmark between 2007 and 2018
–  Positive patch test reactions to formaldehyde and formaldehyde releasers

30 September 2021 – Dermatitis Research Review Issue 6

In this edition we feature:

–  Surveys not reliable to assess AD prevalence
–  There is a significant autoimmune comorbidity in adults with AD
–  Efficacy and safety of JAK inhibitors for the treatment of AD
–  Ocular surface disorders among patients treated with dupilumab
–  Inaugural global best practices from the Atopic Dermatitis Quality of Care Initiative
–  Abrocitinib, dupilumab and upadacitinib the most effective therapies for moderate-to-severe disease
–  Mixed results to IL-12/23 pathway targeting with ustekinumab
–  Patients with AD are at increased risk of developing CVD
–  Dupilumab elicits rapid improvement in the extent and signs of AD in paediatric patients
–  Crisaborole is safe and efficacious for long-term treatment of mild-to-moderate AD

19 August 2021Dermatitis Research Review Issue 5

In this edition we feature:

–  Children hospitalised for AD at increased risk of being medicated for psychiatric disorders
–  Topical corticosteroid treatment improves both skin and systematic immune dysfunction
–  Serum immunoinflammatory biomarkers may be prognostic for disease severity
–  Dupilumab combinations elicit response in disease recalcitrant to dupilumab monotherapy
–  Biological therapies for AD
–  Early and long-term effects of dupilumab treatment on circulating T cell functions
–  Comparative safety of systemic immunomodulatory medications
–  Is dupilumab safe to use during pregnancy?
–  Are eosinophil relative count and neutrophil–lymphocyte ratio biomarkers of disease severity?
–  How does COVID-19 impact patients undergoing dupilumab therapy?

30 July 2021Dermatitis Research Review Issue 4

In this edition we feature:

–  Measure Up 1 and 2 demonstrate efficacy and safety of upadacitinib
–  AD Up: upadacitinib safe and efficacious in combination with corticosteroids
–  Bacteriotherapy may be a novel therapeutic for AD
–  Delgocitinib ointment elicits improvements in paediatric patients
–  Recommendations for vaccination for paediatric patients receiving dupilumab
–  Nemolizumab elicits rapid improvement in itch, sleep and skin lesions
–  Stem cell transplant and dupilumab for DOCK8 deficiency-related dermatitis
–  Dupilumab shows efficacy in prurigo nodularis-like AD
–  Significantly increased risk for conjunctivitis in AD
–  Baricitinib confers benefits in itch and sleep as quickly as 24 hours after the first dose

24 June 2021Dermatitis Research Review Issue 3

In this edition we feature:

–  Carer handbook improves confidence of carers of new patients but doesn’t impact disease
–  Therapeutic education in AD: A position paper from the International Eczema Council
–  Cytokines in skin biopsies versus tape strips
–  Preclinical study provides evidence of autoimmune response in some patients with AD
–   “Face mask dermatitis” due to compulsory facial masks
–  Could probiotic supplementation offer an efficacious treatment for AD?
–  Low bioavailability of topically applied ruxolitinib cream confirms safety profile
–  Positive patient-reported outcomes for abrocitinib monotherapy
–  Is there a relationship between obesity and AD?
–  No increased risk of VTE in AD

26 May 2021 – Dermatitis Research Review – Issue 2

In this edition we feature:

–  Early life exposure to antibiotics increases the risk for AD
–  Association of AD severity with learning disability in children
–  Does AD impact educational attainment?
–  Moderate-to-severe AD in adults has a high economic and psychosocial burden
–  Real-world effectiveness of dupilumab for moderate-to-severe AD
–  Baricitinib safety profile in adults confirmed by integrated analysis of eight clinical trials
–  Dupilumab therapy safe and effective for elderly patients
–  Real-world experience and laboratory monitoring of dupilumab
–  Efficacy and safety of methotrexate in moderate-to-severe AD
–  Weight reduction significantly improves AD severity

31 March 2021 – Dermatitis Research Review – Issue 1

In this edition we feature:

–  The global burden of AD
–  Lack of clinical trial data in older adults for systemic AD medications
–  Postmarketing study finds no increased risk of keratinocyte carcinoma with TCI use
–  Patients with severe AD have an increased risk of systemic infections
–  Dupilumab associated with higher risk of conjunctivitis
–  Conjunctivitis in dupilumab clinical trials for adolescents
–  LIBERTY AD PRE-SCHOOL finds dupilumab efficacious and safe in paediatric patients
–  Pooled analysis finds baricitinib safe in adult patients
–  BREEZE-AD7 confirms efficacy of oral 4 mg baricitinib with background TCS use
–  Tapinarof cream may provide a novel therapeutic option for AD